New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
07:05 EDTLLYEli Lilly and Immunocore partner to develop cancel therapies
Eli Lilly and Immunocore today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Immunocore will receive an upfront fee of $15M per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10M and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
10:52 EDTLLYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTLLYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 14, 2015
09:22 EDTLLYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:44 EDTLLYInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
06:04 EDTLLYEli Lilly, Sanford-Burnham to investigate immunological therapies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use